Table 1.

IC₅₀ (nM) for commercially available multikinase inhibitors studied in thyroid cancer

	RET	RET/PTC3	VEGFR-1	VEGFR-2	VEGFR-3	c-Met	EGFR	FGFR2	BRAF V600E	c-Kit
Cabozantinib29	5.2		12.2	0.035	6	1.3–14.6				4.6
Lenvatinib30	6.4		4.7	3	2.3			27		85
Pazopanib31			10	30	47					74
Sorafenib32–35	5.9	50	26	90	20				45	68
Sunitinib36–38		224	2	9	17					1–10
Vandetanib39,40		100	1,600	40	110		500

Abbreviations: BRAF, v-raf murine sarcoma viral oncogenes homolog B1; EGFR, epidermal growth factor receptor; FGFR, fibroblast growth factor receptor; IC₅₀, median inhibitory concentration; PTC, papillary thyroid carcinomas; RET, rearranged during transfection; VEGFR, vascular endothelial growth factor receptor.